BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 окт 2023 07:00:41 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 сен 2023 07:00:46 Источник Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

23 авг 2023 16:01:54 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 авг 2023 16:01:28 Источник Nasdaq GlobeNewswire

BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update

03 авг 2023 07:00:58 Источник Nasdaq GlobeNewswire

BioCryst to Report Second Quarter 2023 Financial Results on August 3

20 июл 2023 07:00:37 Источник Nasdaq GlobeNewswire

BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

19 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst to Participate in the 2023 US HAEA National Summit

17 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 июл 2023 07:00:12 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 июн 2023 07:00:42 Источник Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conference

01 июн 2023 07:00:45 Источник Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

31 май 2023 07:02:04 Источник Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

22 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 май 2023 16:01:01 Источник Nasdaq GlobeNewswire

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

03 май 2023 07:00:55 Источник Nasdaq GlobeNewswire

BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)

27 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

BioCryst to Report First Quarter 2023 Financial Results on May 3

19 апр 2023 07:00:27 Источник Nasdaq GlobeNewswire

BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon

18 апр 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

12 апр 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 апр 2023 07:00:36 Источник Nasdaq GlobeNewswire